Positive high-level results from the ADAURA phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2 and 3a) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.
